Northern Trust Corp Acquires 42,170 Shares of Artivion, Inc. (NYSE:AORT)

Northern Trust Corp boosted its stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 10.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 463,250 shares of the company's stock after purchasing an additional 42,170 shares during the quarter. Northern Trust Corp owned about 1.11% of Artivion worth $13,244,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its stake in Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock worth $32,000 after acquiring an additional 786 shares in the last quarter. R Squared Ltd bought a new position in shares of Artivion during the 4th quarter worth approximately $39,000. Arcadia Investment Management Corp MI bought a new position in shares of Artivion during the 4th quarter worth approximately $43,000. Venturi Wealth Management LLC bought a new position in shares of Artivion during the 4th quarter worth approximately $78,000. Finally, KBC Group NV lifted its holdings in shares of Artivion by 80.4% in the 4th quarter. KBC Group NV now owns 2,813 shares of the company's stock worth $80,000 after purchasing an additional 1,254 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

Insider Transactions at Artivion

In other news, CFO Lance A. Berry sold 3,259 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $89,003.29. Following the completion of the sale, the chief financial officer now owns 75,805 shares of the company's stock, valued at approximately $2,070,234.55. This trade represents a 4.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Marshall S. Stanton sold 10,548 shares of the firm's stock in a transaction on Friday, May 9th. The stock was sold at an average price of $29.13, for a total value of $307,263.24. Following the completion of the transaction, the senior vice president now owns 105,332 shares in the company, valued at $3,068,321.16. This represents a 9.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 101,347 shares of company stock valued at $2,663,486. Insiders own 7.60% of the company's stock.

Artivion Trading Down 0.8%

AORT traded down $0.22 during trading hours on Wednesday, reaching $28.95. The company's stock had a trading volume of 23,519 shares, compared to its average volume of 322,685. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $32.33. The stock has a market cap of $1.24 billion, a PE ratio of -1,442.95 and a beta of 1.54. The business's 50-day moving average is $24.87 and its 200-day moving average is $27.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The business had revenue of $98.98 million for the quarter, compared to analyst estimates of $94.81 million. As a group, equities research analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Needham & Company LLC reissued a "buy" rating and issued a $32.00 price objective on shares of Artivion in a report on Tuesday, May 6th. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. JMP Securities reaffirmed a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a research note on Tuesday, May 6th. Finally, Stifel Nicolaus reduced their target price on Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a research note on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Artivion currently has an average rating of "Buy" and an average target price of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.